Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T cell-depleted non-myeloablative allogeneic stem cell transplantation with lenalidomide with or without bortezomib and subsequent DLI in relapsed multiple myeloma
NL-OMON36688Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, bortezomib, alemtuzumab, melphalan, fludarabine in multiple myeloma (MM), sponsored by HOVON. Started Sep 2011; status: active, not recruiting.
02
Drugs
lenalidomidebortezomibalemtuzumabmelphalanfludarabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON36688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36688.